Page 133 - 2018 SP Product Guide
P. 133

Recommended Action  Monitor (very low level of risk).  Monitor (low level of risk at typical doses).  Monitor (low level of risk). B  Monitor (low level of risk).  Monitor (low level of risk).  Monitor (low level of risk).  Monitor (low level of risk).  Monitor (low level of risk). Monitor (low level of risk at typical doses).  Monitor (low level of risk).  Monitor (low level of risk).  Monitor (low level of risk).  Contraindicated. Monitor (medium level of risk) when









                                           pressure in normotensive and hypertensive animals. 18,19  Clinical data from weight management trials: no effect
                                          Theoretical concern based on ability of high doses of forskolin and standardized Coleus extract to lower blood
                                     antiplatelet activity in an animal model (oral doses: standardized Coleus extract and forskolin). 16  More recent
                                    Theoretical concern initially based on in vitro antiplatelet activity of active constituent forskolin, and in vivo
                                       in vivo animal research: standardized Coleus extract reduced the anticoagulant activity of warfarin. 17
                           Clinical trial with healthy volunteers (water-based extract, A  dried herb equivalent: 12 g/day). 14
                              Clinical study with healthy volunteers using 150 mg/day of isolated constituent (baicalin). 15









                                              clinical studies conducted with hypotensive medication. on blood pressure in three trials, trend toward lower blood pressure in one small study. 20,21  No experimental or  Theoretical concern based on ability of forskolin to activate increased intracellular cyclic AMP in vitro. 22 Clinical trials with healthy volunteers: effect on drug levels conflicting – increased (double-strength juice C ,  240 mL tds; defined as a weak interaction D )









               Basis of Concern  Case reports. 13                                      undetectable viral load. 41  observed on plasma concentration. 47













               Potential Interaction  May reduce serum levels of thyroxine.  May increase drug levels.  May decrease drug levels.  May alter response to drug.  May potentiate effects of drug.  May potentiate effects of drug.  May increase drug levels.  May increase side effects of drug. May alter INR (most frequently increase).  May potentiate effect of drug.  HIV non-nucleoside transcriptase inhibitors  eg etravirine: May alter drug levels.  HIV protease inhibitors  eg darunavir: Ma







                   Celery Seed  Apium graveolens  Chinese Skullcap  Scutellaria baicalensis  Coleus  Coleus forskohlii  Antiplatelet and anticoagulant   Hypotensive medication  Cranberry  Vaccinium macrocarpon  Dong Quai  Angelica sinensis, Angelica polymorpha Echinacea  Echinacea angustifolia, Echinacea purpurea  Immunosuppressant medication









               Drug  Thyroxine  Losartan  Rosuvastatin  drugs  Prescribed medication  Midazolam  Simvastatin  Warfarin  Warfarin  Antiretroviral drugs  Midazolam  Digoxin




            132   MediHerb  Product Catalog 2018  • Herb-Drug Interaction Chart
                     ®
   128   129   130   131   132   133   134   135   136   137   138